Trials / Completed
CompletedNCT00839852
A Study of Cariprazine in Patients With Chronic Stable Schizophrenia
A Long-term, Open-label Extension Study of the Safety and Tolerability of RGH-188 (Cariprazine) in Patients With Schizophrenia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 97 (actual)
- Sponsor
- Forest Laboratories · Industry
- Sex
- All
- Age
- 18 Years – 61 Years
- Healthy volunteers
- Not accepted
Summary
This is an outpatient study to evaluate the long-term safety, tolerability, and pharmacokinetics of cariprazine in patients with schizophrenia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cariprazine | Cariprazine was supplied in capsules. |
Timeline
- Start date
- 2009-05-31
- Primary completion
- 2010-08-31
- Completion
- 2010-08-31
- First posted
- 2009-02-10
- Last updated
- 2019-08-22
- Results posted
- 2019-08-22
Locations
65 sites across 5 countries: United States, India, Malaysia, Russia, Ukraine
Source: ClinicalTrials.gov record NCT00839852. Inclusion in this directory is not an endorsement.